MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Scales"

  • 2017 International Congress

    Acquisition, Validation and Preprocessing of Wrist-Worn Sensor Data in Patients with Parkinson’s Disease and Healthy Controls

    D. Pichler, M. Lang, D. Kulić, F. Pfister, G. König, T. Um, A. Ahmadi, S. Endo, F. Achilles, K. Abedinpour, K. Bötzel, A. Ceballos-Baumann, S. Hirche, U. Fietzek (Munich, Germany)

    Objective: We describe relevant aspects and data processing steps for accelerometry and gyroscopy recordings made with a wrist-worn low-cost sensor device. In order to generalize…
  • 2017 International Congress

    Variability of spiral tremor during daily life of subjects with Essential Tremor

    J. Thompson-Westra, T. Wu, H. Cao, A. Pigg, G. Leodori, F.A. Vial Undurraga, M. Hallett, D. Haubenberger (Bethesda, MD, USA)

    Objective: To explore the long-term variability and reliability of tremor severity in Archimedes spirals in patients with Essential Tremor (ET). Background: ET affects activities of…
  • 2017 International Congress

    Efficacy of rotigotine as measured by individual Unified Parkinson’s Disease Rating Scale II and III items: a post-hoc analysis

    M. Asgharnejad, H. Pesch, E. Dohin (Raleigh, NC, USA)

    Objective: The key aim was to assess the efficacy of rotigotine (RTG) transdermal patch on individual items of Unified Parkinson’s Disease Rating Scale (UPDRS) II…
  • 2017 International Congress

    Validation of a performance-based assessment of functional ability related to cognition in Parkinson’s disease

    S. Holden, L. Medina, B. Hoyt, S. Sillau, J. Goldman, D. Weintraub, B. Kluger (Aurora, CO, USA)

    Objective: Validate the University of California San Diego Performance-Based Skills Assessment (UPSA) in Parkinson's disease (PD) Background: Diagnostic criteria for PD dementia (PDD) require significant…
  • 2017 International Congress

    Sample size estimation for clinical trials in de novo Parkinson’s disease (PD): Results from the Parkinson’s Progression Markers Initiative (PPMI) Study

    T. Simuni, C. Caspell-Garcia, N. Seedorff, C. Coffey, S. Lasch, B. Mollenhauer, C. Tanner, K. Kieburtz, K. Marek (Chicago, IL, USA)

    Objective: To use clinical and biological data from PPMI to estimate sample size for disease modification studies in de novo PD  Background: One barrier to…
  • 2017 International Congress

    Classification of neurocognitive impairment in Spanish speaking Parkinson’s disease patients

    S. Anderson, C. Bermudez, N. Sun-Suslow, L. Segala, H. Moore, C. Singer, J. Jagid, G. Rey, B. Levin (Chicago, IL, USA)

    Objective: To examine differences between United States (US) and Latin American (LA) norms classifying cognitive impairment using standardized neuropsychological measures to assess cognition in Parkinson’s…
  • 2017 International Congress

    Five year longitudinal change in the MDS-UPDRS scores in early Parkinson’s disease participants: Results from the PPMI Study

    T. Simuni, C. Caspell-Garcia, N. Seedorff, C. Coffey, S. Lasch, B. Mollenhauer, C. Tanner, K. Kieburtz, K. Marek (Chicago, IL, USA)

    Objective: To determine the longitudinal change in the Movement Disorder Society –Unified Parkinson’s Disease Rating Scale (MDS-UPDRS) in Parkinson’s disease (PD) participants who were untreated…
  • 2017 International Congress

    Which self-report motor experiences of daily living best predict objective motor function in patients with Parkinson’s disease?

    S. Anderson, J. Goldman, S. Luo, A. Negron, C. Goetz, G. Stebbins (Chicago, IL, USA)

    Objective: To identify the most important self-reported motor experience predictors of objective measures of motor impairment in patients with Parkinson's disease (PD). Background: The MDS-UPDRS has…
  • 2017 International Congress

    Improving Clinical Trials Through Patient Input: Outcomes of a Partnership Between Pfizer and the Parkinson’s Disease Foundation

    K. Schroeder, M. Fenney, D. Gray, T. Rolph, S. Sohur, V. Todaro (New York, NY, USA)

    Objective: To identify the outcomes of the partnership between Pfizer and the Parkinson’s Disease Foundation (PDF), which was designed to 1. increase understanding of the…
  • 2017 International Congress

    Objective measurement of upper extremity bradykinesia using the keyboard-based dexterity test

    S.-k. Song, J.-H. Kang (Jejusi, Republic of Korea)

    Objective: To objectively assess the bradykinesia of upper extremity using the Objective Movement Disorder Measurement (OMDM)-Dexterity test Background: Bradykinesia is one of the clinical hallmarks…
  • « Previous Page
  • 1
  • …
  • 28
  • 29
  • 30
  • 31
  • 32
  • …
  • 35
  • Next Page »

Most Viewed Abstracts

  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • #24970 (not found)
  • Life expectancy with and without Parkinson’s disease in the general population
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • To be or not to bupropion: a drug-induced parkinsonism?
    • Help & Support
    • About Us
    • Cookies & Privacy
    • Wiley Job Network
    • Terms & Conditions
    • Advertisers & Agents
    Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
    Wiley